Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript Motley Fool - Wed May 1, 6:30PM CDT

SRPT earnings call for the period ending March 31, 2024.

SRPT : 133.66 (+2.32%)
Sarepta Therapeutics: Q1 Earnings Snapshot AP - Wed May 1, 3:20PM CDT

Sarepta Therapeutics: Q1 Earnings Snapshot

SRPT : 133.66 (+2.32%)
1 Top Growth Stock to Buy and Hold for 10 Years Motley Fool - Wed May 1, 8:15AM CDT

This company's lineup might look very different in a decade, but the end result will be the same for investors.

SRPT : 133.66 (+2.32%)
2 Biotech Stocks to Buy Hand Over Fist in April Motley Fool - Sat Apr 6, 7:45AM CDT

These drugmakers have made important moves over the past year.

AMGN : 311.29 (+11.82%)
SRPT : 133.66 (+2.32%)
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? Motley Fool - Wed Mar 13, 7:00AM CDT

The threat is still emerging, but it could be significant.

SRPT : 133.66 (+2.32%)
RGNX : 16.83 (+1.14%)
Got $1,000? Buy These Hot Growth Stocks Before They Take Off. Motley Fool - Fri Mar 8, 4:45AM CST

These stocks haven't been able to get much traction lately, even though they clearly deserve to now.

SRPT : 133.66 (+2.32%)
ENPH : 114.20 (+7.67%)
GOOG : 168.99 (+0.31%)
GOOGL : 167.24 (+0.37%)
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst Motley Fool - Mon Mar 4, 8:47AM CST

The upcoming regulatory decision on its latest drug could be big.

SRPT : 133.66 (+2.32%)
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript Motley Fool - Wed Feb 28, 11:00PM CST

SRPT earnings call for the period ending December 31, 2023.

SRPT : 133.66 (+2.32%)
Sarepta Therapeutics: Q4 Earnings Snapshot AP - Wed Feb 28, 3:23PM CST

Sarepta Therapeutics: Q4 Earnings Snapshot

SRPT : 133.66 (+2.32%)
Is It Too Late to Buy Sarepta Therapeutics Stock? Motley Fool - Wed Feb 28, 6:15AM CST

The company's hyperfocus on its core area could continue to be highly lucrative.

SRPT : 133.66 (+2.32%)

Barchart Exclusives

2 Small-Cap Stocks With 40% to 60% Upside Barchart - Sat May 4, 2:45PM CDT
Wall Street believes these two growth stocks will soar, driven by the demand for their products. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot